These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20592732)

  • 1. Excitement grows for potential revolution in hepatitis C virus treatment.
    Opar A
    Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
    [No Abstract]   [Full Text] [Related]  

  • 2. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 3. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R; Fagiuoli S; Sacchi P
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract]   [Full Text] [Related]  

  • 4. New developments in HCV therapy.
    Kronenberger B; Zeuzem S
    J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infectious diseases. First specific drugs raise hopes for hepatitis C.
    Enserink M
    Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutics: new drugs hit the target.
    Schlütter J
    Nature; 2011 Jun; 474(7350):S5-7. PubMed ID: 21666733
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase 3 study results released for telaprevir and HCV.
    AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
    [No Abstract]   [Full Text] [Related]  

  • 8. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
    Lange CM; Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):60-7. PubMed ID: 21194084
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis C virus therapies.
    Smith RE
    Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
    [No Abstract]   [Full Text] [Related]  

  • 11. Viral hepatitis C in 2014--the beginning of the end?
    Prelipcean CC; Gogălniceanu P; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):272-8. PubMed ID: 25076687
    [No Abstract]   [Full Text] [Related]  

  • 12. [A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
    Manns M
    MMW Fortschr Med; 2011 Jul; 153(29-31):17. PubMed ID: 21830729
    [No Abstract]   [Full Text] [Related]  

  • 13. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
    Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun SC; Deshpande M; Rhodes G; Miller MD
    J Viral Hepat; 2011 May; 18(5):338-48. PubMed ID: 20456634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
    Fernández-Yunquera A; Rincón D; Salcedo M; Bañares R
    Rev Esp Quimioter; 2013 Sep; 26(3):189-92. PubMed ID: 24080883
    [No Abstract]   [Full Text] [Related]  

  • 15. HCV RNA viral load assessments in the era of direct-acting antivirals.
    Cobb B; Pockros PJ; Vilchez RA; Vierling JM
    Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era.
    Soriano V; Labarga P; Vispo E; Fernández-Montero JV; Barreiro P
    Infect Dis Clin North Am; 2012 Dec; 26(4):931-48. PubMed ID: 23083825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2283-4. PubMed ID: 17570199
    [No Abstract]   [Full Text] [Related]  

  • 18. New hepatitis C regimen stimulates changes in therapy management.
    Reinke T
    Manag Care; 2011 Dec; 20(12):41-2. PubMed ID: 22259876
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of hepatitis C virus mutants resistant to protease inhibitors among Polish HCV genotype 1-infected patients.
    Zabek P; Opoka-Kegler J; Baka M; Dyda T; Stańczak GP; Stańczak JJ
    Przegl Epidemiol; 2013; 67(3):411-3, 521-3. PubMed ID: 24340552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New times for the treatment of chronic hepatitis C].
    Gerstoft J; Fomsgaard A
    Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.